Principle of Assay
Human Cancer Antigen 242 ELISA Kit (A302607) is a 4 hour sandwich Enzyme-Linked Immunosorbent Assay (sELISA) designed for the in vitro quantitative determination of human Cancer Antigen 242 in serum, plasma, tissue homogenates, and other biological fluids. A 96-well microtiter plate has been pre-coated with an antibody specific for Cancer Antigen 242. Standards and samples are added to the wells, where Cancer Antigen 242 binds to the immobilized capture antibody. Following incubation, unbound components are removed by washing and a biotinylated detection antibody specific for Cancer Antigen 242 is added to the wells. The detection antibody binds the captured Cancer Antigen 242 to form an antibody-antigen-antibody sandwich complex. After further incubation and washing, HRP-Streptavidin conjugate is added to the wells. TMB substrate solution is then added to visualize the HRP enzymatic reaction. This produces a blue-coloured product that changes to yellow following addition of acidic stop solution. The intensity of the yellow colour is directly proportional to the amount of Cancer Antigen 242 captured in each well. The concentration of Cancer Antigen 242 is calculated by reading the absorbance at 450 nm and comparing the values with the standard curve.